Literature DB >> 21951792

[Current status and development of miRNA and siRNA research on gastric cancer].

Miao He1, Zi-Wei Wang.   

Abstract

RNA interference (RNAi) is an important topic of epigenetics research in post-genome period. RNAi works as a post-DNA replication regulator for gene expression, and it is related to the occurrence and development of malignant tumors. The most usual participators of RNAi are MicroRNA (miRNA) and small interference RNA (siRNA). This review summarizes the basic theory of miRNA and siRNA, and provides recent progresses of RNAi research on gastric cancer. RNAi analysis and technique not only act as powerful tools for studying gene function and action mechanism, but also have diagnostic and therapeutic potential in gastric cancer, even in all kinds of tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951792     DOI: 10.3724/sp.j.1005.2011.00925

Source DB:  PubMed          Journal:  Yi Chuan        ISSN: 0253-9772


  4 in total

Review 1.  MicroRNAs in gastric cancer: from benchtop to bedside.

Authors:  Fuyi Tong; Peng Cao; Yuan Yin; Suhua Xia; Rensheng Lai; Shenlin Liu
Journal:  Dig Dis Sci       Date:  2013-10-10       Impact factor: 3.199

2.  Inhibitory effect of siRNA-Annexin A7 on growth, migration, and invasion in BGC823 cells and gastric cancer xenograftsin nude mice.

Authors:  Hu-Fang Yuan; Yong Li; Bi-Bo Tan; Qun Zhao; Li-Qiao Fan; Zhao-Jie An
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

3.  Regulatory effects of miRNA on gastric cancer cells.

Authors:  Ouyang Yang; Jianhua Huang; Sun Lin
Journal:  Oncol Lett       Date:  2014-06-05       Impact factor: 2.967

4.  Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy.

Authors:  Ran Zhao; Sujuan Du; Ying Liu; Cong Lv; Yongli Song; Xinchun Chen; Bing Zhang; Dan Li; Shan Gao; Wei Cui; Maksim V Plikus; Xiaohua Hou; Kaichun Wu; Zhanju Liu; Zhihua Liu; Yingzi Cong; Yuan Li; Zhengquan Yu
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.